Film-coated tablets containing the same excipients than FORXIGA® 10 mg excipients (but not dapagliflozin) clinical trials

Impact of dapagliflozin on vascular function in chronic kidney disease patients - (DAPA-VASC)

This study is looking at how a medicine called dapagliflozin might affect blood vessels in people with long-term kidney disease. Researchers want to see if it improves how well blood vessels relax and widen over 12 weeks compared to a dummy pill.